Search Results
483 results found for "Cost-efficient medications https://simplemedrx.top"
- ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials & Future Growth
Dr. de Kergrohen holds a Medical Degree from Université Louis Pasteur in Strasbourg and a MBA from INSEAD Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board
Smith is recognized as one of the world’s most cited researchers in the fields of Alzheimer’s disease Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41
Neuropsychopharmacology is an international scientific journal and the official publication of the American Against Amyloid-beta (25-35)-Induced Toxicity in Mice,” can be viewed on the publication’s web site at http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on AD 2008
Neuroprotection is the most important component necessary to attain long-term benefits in neurodegenerative Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently
advanced-stage subcutaneous mice models reached approximately 250 cubic millimeters in size (day 22 post stopped when tumors of the control group had grown to approximately 1,000 cubic millimeters (day 33 post achieved after ANAVEX 7-1037 had been administered seven times at a statistically significant level (post urgent medical needs like efficacy, drug resistance, side effects, administration and affordability, Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008
With these partnerships, ANAVEX is able to outsource parts of the R&D process to drive capital efficiency Alexandre Vamvakides became Chief Scientific Officer and Director, and ANAVEX added a distinguished, medically pharmacology, a M.Sc. in biochemistry and a Ph.D. in molecular pharmacology all from the University of Paris,Medical Cameron Durrant, a medically trained MBA with an entrepreneurial background and major international pharmaceutical and an additional 50 compounds at various early stages of discovery, ANAVEX has one of the industry’s most
- Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease
results were presented at the Neuroscience 2007 conference in San Diego, California, and are available at https About Alzheimer’s disease Alzheimer’s disease is the most common cause of dementia and is characterized Medications currently available to treat Alzheimer’s disease include acetylcholinesterase inhibitors Both types of medications only treat symptoms of the disease — they do not stop the onset and progression In conclusion, there are very real and unmet medical requirements for drug therapies to treat Alzheimer
- Anavex Strengthens Board of Directors
Durrant is a medically trained MBA who has a unique entrepreneurial background coupled with major international
- ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects
results were presented at the 15th Euroconference on Apoptosis (Portoroz, Slovenia), and are available at https reverse the progression of the disease, which have a novel mode of action that could fulfill some of the most urgent medical needs like efficacy, drug resistance, side effects, administration and affordability,
